Mirum Pharmaceuticals has delivered a very strong share price gain over the past five years, yet the stock now screens as roughly fairly priced on traditional valuation multiples while still earning a high overall value score. That mix raises the question of whether recent news around its lead products is already fully reflected in the current price.

• The stock has returned about 6x over five years, which puts recent short term pullbacks in a much longer context of very strong gains.
• Investor expectations today seem anchored in ongoing revenue growth from LIVMARLI, while the extra regulatory work requested for volixibat may cap how much value the market is willing to assign to the broader pipeline for now.
• Mirum Pharmaceuticals currently passes 5 out of 6 valuation checks, which suggests the broader set of metrics still leans on the inexpensive side despite the big long term run.

The stock's next move may depend on whether those valuation checks continue to support Mirum Pharmaceuticals at close to the current share price after the recent news is fully absorbed.

Does Mirum Pharmaceuticals Look Fairly Valued on Sales?

P/S is often the cleaner yardstick for Mirum Pharmaceuticals because the company is still reporting losses, so earnings-based ratios are less informative. On this measure, Mirum trades at about 10.4x sales, which sits below the Biotechs industry average of roughly 11.4x and also below the peer group average of about 14.9x.

The fair P/S ratio, which blends the company’s growth profile, margins, size and risk into one benchmark, comes out at about 9.7x. That is only a small step under the current 10.4x level, so the gap between price and this tailored reference point is modest. Despite the recent uplift in sentiment after Mirum raised 2026 sales guidance, the stock still prices close to what this framework suggests is a reasonable multiple for its revenue base.

On the P/S multiple, Mirum Pharmaceuticals appears roughly fairly valued relative to both its own fundamentals and the wider Biotechs sector.

The Mirum Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Mirum Pharmaceuticals pick up where the valuation puzzle leaves off and explain what path for growth, margins and earnings would need to occur for the stock to be worth significantly more or less than it is today, based on community views on the company’s future. Each narrative links its number to a clear view on how Mirum Pharmaceuticals' growth, profitability and risks could evolve, which you can revisit as fresh information arrives.

One of the top community narratives on Mirum Pharmaceuticals: 16% undervalued

"Intensifying global scrutiny on drug pricing and healthcare expenditures poses a substantial threat to Mirum's long-term revenue growth, as reimbursement for rare disease therapies is increasingly challenged..."

Do you think there's more to the story for Mirum Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Mirum Pharmaceuticals now sits in a zone where the market multiple view points to about right pricing rather than a clear discount. The high overall value score hints that broader checks still lean supportive, even after a very strong multi year move and recent volatility. From here, the key question is whether revenue and margin delivery from LIVMARLI and progress on the wider pipeline justify holding this kind of sector level P/S multiple. The debate between bulls and bears largely comes down to how confident you are that current expectations for future product uptake and regulatory milestones can be sustained without a reset in the valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.